hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain

Egelrud, T., Brattsand, M., Kreutzmann, M., Walden, M., Vitzithum, K., Marx, U. C., Forssmann, W. G. and Mägert, H. J. (2005) hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain. British journal of dermatology, 153 6: 1200-1203. doi:10.1111/j.1365-2133.2005.06834.x

Author Egelrud, T.
Brattsand, M.
Kreutzmann, M.
Walden, M.
Vitzithum, K.
Marx, U. C.
Forssmann, W. G.
Mägert, H. J.
Title hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain
Journal name British journal of dermatology   Check publisher's open access policy
ISSN 1365-2133
Publication date 2005-06
Sub-type Article (original research)
DOI 10.1111/j.1365-2133.2005.06834.x
Volume 153
Issue 6
Start page 1200
End page 1203
Total pages 4
Place of publication London
Publisher British Association of Dermatologists
Language eng
Subject 0601 Biochemistry and Cell Biology
Abstract Background Several skin diseases and atopic disorders including Netherton syndrome and atopic dermatitis have been associated with mutations and deviations of expression of SPINK5, the gene encoding the human 15-domain serine proteinase inhibitor LEKTI. The biochemical mechanisms underlying this phenomenon have not yet been fully clarified. Objectives To identify target proteinases of LEKTI important for processes of desquamation and inflammation of the skin which will enable the development of specific drugs. Methods The inhibitory activities of LEKTI domains 6 and 15 were tested on a number of commercially available serine proteinases and also on the purified kallikreins hK5 and hK7. In addition, recombinant hK5 was used. Results LEKTI domain 6 is a potent inhibitor of hK5 and hK7, whereas LEKTI domain 15 exhibits inhibitory activity on plasmin. hK5 and hK7 in particular are relevant to skin disorders. Conclusions The inhibition of hK5 and hK7 by LEKTI domain 6 indicates an important regulatory role of LEKTI in processes of skin desquamation and inflammation, which may explain the severe pathological symptoms associated with abnormalities of SPINK5 and/or its expression. Thus, LEKTI represents a potential drug for the treatment of these disorders.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 71 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 73 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 10 Feb 2009, 17:25:07 EST by Laura McTaggart on behalf of Institute for Molecular Bioscience